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The covalent binding of pyridoxal5’-phosphate (PLP) to human serum albumin (HSA) is important in the regulation of PLP metabolism. Inplasma, 
PLP is bound to HSA at a single high-affinity and at two or more nonspecific sites. To characterize the primary PLP binding site, HSA was incubated 
with [‘HIPLP, and the Schiff base linkage was reduced with potassium borohydride. Tryptic peptides were purified, and the major labeled peptide 
was sequenced. Amino acid analysis confirmed a homogeneous peptidc Leu-Asp-Glu-Lcu-Arp-As~GIu-Gly-Xaa-Als-Ser-Ser-Ala-Lys which 
corresponds to residues 182-195 of HSA. The data indicate that LyslYo is the primary PLP binding site. This Lys residue is distinct from other 
sites of covalent adduct formation; namely, the primary sites for nonenzymatic glycosylation (LysJz5) and acctyla.tion by aspirin (L~s’~~). 
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1. INTRODUCTION the binding of PLP to HSA, but do inhibit FLP binding 
to BSA [3]. 
Pyridoxal phosphate (PLP), the major cofactor form 
of vitamin B6, is required in many of the reactions of 
amino acid metabolism. In plasma, more than 95% of 
the circulating PLP is bound to human serum albumin 
(HSA) [I]. Since PLP bound to HSA is protected from 
hydrolysis by phosphatases [ 121, HSA serves as a re- 
servoir and mediates PLP transport o tissues. Although 
PLP binds as a Schiff base to both BSA and HSA, 
recent studies uggest that PLP binds differently to HSA 
than it does to BSA [3]. Equilibrium binding data indi- 
cate a single high affinity and two or more nonspecific 
sites for PLP in HSA [3], In previous studies, PLP was 
shown to be localized to a region of HSA containing 
residues 162-197, but sequencing was not performed [4]. 
In addition to PLP, HSA also forms covalent adducts 
with cysteine, aspirin and glucose [S]. Cystaine forms a 
disulfide bond with CysJq, aspirin acetylates Lys’“’ and 
glucose forms a ketoamine derivative at Lys535 [S,7]. The 
present study was undertaken to identify the PLP bind- 
ing site on HSA and determine its relationship to co- 
valent adduct formation at L~s’~~ (aspirin) and Lys”” 
(glucose). Tryptic peptidcs of radiolabeled HSA were 
purified by high performance liquid chromatography 
(HPLC) and characterized by amino acid analysis and 
sequencing of pyridoxylated peptides. 
In contrast, BSA contains two high affinity PLP bind- 
ing sites, one of which has been identified as LYS”~ or 
LysF, a site for which there is no homologous Lys in 
HSA [S]. The specificity of high affinity covalent bind- 
ing of PLP to BSA appears to be dependent on interac- 
tions of the anionic phosphate ester with neighboring 
cationic lysine or arginine residues in the protein [6]. 
The role of the phosphate ester in binding at the 
primary site also appears to be different in HSA than 
in BSA since phosphorylatcd compounds do not inhibit 
2. MATERIALS AND METHODS 
2.1. Mf2teriub 
Human serum albumin (Fraction V) was purchased from the Amer- 
ican Red Cross and further purified by the method of Feldhoff and 
Ledden [8]. PLP was obtained from Sigma (St. Louis, MO). 
[‘HISodium borohydride (348 mCi/mmol) was purchased from NEN 
(Boston, MA). All experiments involving PLP and PLP~modificd 
HSA were performed ino room illuminated only with gold fluorescent 
lights (Sylvania F15TS-GO). Phosphate-buffered saline (PBS) con- 
tained sodium chloride, 8.0 g/l; potassium chloride, 0.2 dl; sodium 
phosphate dibasic, I. I5 &Ii; potassium phosphate monobasic, 0.2 B/I; 
and sodium azide, 0.2 @I. 
2.2. Prcparutiorl and ptrificarion of [‘ifjPLP 
Abbreviarions: PLP, pyridoxal S-phosphate; HSA, human serum aI_ 
bumin; BSA, bovine serum albumin; NEG, nonenzymatic glycosyla- 
Lion; PBS, phosphate-buffered saline. 
Currevpdcnce oddrcss: R.C. Feldhoff, Department of Biochemistry, 
School of Medicine, University of Louisville, Louisville, KY 40292 
(USA). Fax: (I) (502) 588-6222, 
[‘H]PLP was synthesized by reduction of PLP with [3H]sodium 
borohydride followed by oxidation with manBnese dioxide [9]. The 
[“H]PLP was purified by chromatography onDowex AG-1X2,200- 
400 mesh (Rio-Rad Labs, Richmond, CA) [IO]. The purity of the 
radiolabeled PLP was determined by HPLC using a Spectra Physics 
8700XR system with a Vydac 40lTD cation-exchange column [l 11. 
The effluent was reacted with sodium bisulfite, and the fluorescence 
lvas monitored at 400 nm following excitation at 332 nm. Radioac- 
266 PuDfislwd by ElsesLr Scknca Pubhlwrs B. V. 
Volume 298, number 2,3 FEBSLE’TTERS February 1992 
tivity was determined by liquid scintillation counting. At least 91% of 
the total fluorescence and 92% of the total radioactivity eluted from 
the HPLC column at the lime corresponding toa PLP standard. The 
specitic radioactivity was IS.6 mCi/mmol, 
2.3. L-ubelittg of PLP bhding sires on HSA 
HSA (50 mg) was reacted with an equivalent molar amount of PLP 
(0.75pmoI containing4.2,Ki [‘H]PLP)in PBS, pH 7.4, for I Ii at room 
temperature. The sample was then reacted for I5 min with 7.5 pmol 
potassium borohydride to reduce the Schiff base formed between HSA 
and PLP. The sample was dialyzed exhaustively against 25 mM am- 
monium bicarbonate, pH 8.0, and lyophilized. The protein specific 
activity (= 180,000 dpm/mg) corresponded toa 0.9:l PLPlHSA ratio. 
2.4. Detronrruriott, dis@de cleavage, carboxymertty?ylaiiott, atld cryptic 
digestion 
The pyridoxylated HSA was dissolved in 2.5 ml of I M Tris-MCI, 
pH 8.0. After the addition oCO,5 ml of 10 mM EDTA in 06 N NaOH, 
0,5 ml of 40 mg/ml dithiothreitol, and 2,8G g of guanidine-HCI, the 
mixture was incubated for 1 h at 37°C lodoacetic acid (65 mg) was 
added, and the sample was incubated in the dark, under N:, for I h 
at 37OC. The carboxymcthylatcd sample was dialyzed exhaustively 
against 25 mM ammonium bicarbonate, pH 8.0. Protein conccntra- 
tion was estimated by absorbance at 280 nm using a specific absorb- 
ance of 0.53 mg-’ 8 ml-’ .cm-‘. 
The PLP.HSA (30 mg at 2 m&/ml) was combined with 2.25 ml of 
50 mM octanesulfonic acid, 2.25 ml of 0,25 M ammonium bicar- 
bonate, pH 8.0, and 3.0 ml of TPCK (tosylphcnylalaninethloro~ 
methyl ketone)-treated trypsin (0.1 mg/ml). The protein was digested 
for I8 h at 37’C. No turbidity was observed. 
2.5 Separuriotr arid pwifictrrion of radiolabeled pep/ides 
Radiolabeled peptides were purified on a Waters HPLC system with 
detection at 225 nm. The tryptic pcptidcs were separated first on a 0.46 
x 25 cm Synchropak AX-300 anionmcxchange column (SynChrom, 
Lafayette, IN) using a 30.min linear gradient of 0.02 M to 0.5 M 
ammonium bicarbonate, pH 8.0, and a flow rate of 1.5 ml/min. Ali- 
quots of the collected fractions were assayed for radioactivity, pooled 
and lyophilized. The lyophilized sample was dissolved in 0.5 ml of 25 
mM ammonium bicarbonate and incubated for I h at 37°C with 6 yg 
of alkaline phosphatase (20 U/m& to remove the phosphate group. 
The depliosphorylatedpcptides w re resolved again by anion-cschange 
chromatography. The primnry radioactive fractions from the second 
chromatographic run were purified byreversed-phase HPLC on a 0.46 
x 15 cm Zorba% ODS column (Dupont, Wilmington, DE) using a 
2Ommin li ear gradient of 10% to 50% acetonitrile (0.1% to 0.0075% 
trifluoroacetic acid) at a flow rate of 1 .O ml/min. 
2.G Peptlde seqtrcnce afialysis 
The purified rddiolabeied peptide was sequenced using an Al31 
(Foster City, CA) 470A/l20A gas-phase protein sequencer. Approxi- 
mately I nmol of the major radiolabeld peptide was sequenced. The 
amino acid sequence was confirmed by amino acid analysis using a 
Waters Pica Tag System (Milford, MA), 
3. RESULTS 
Fig. 1. shows the purification of a peptide containing 
the major PLP binding site in HSA. The elution profile 
of radiolabeled tryptic peptides from anion-exchange 
HPLC appears in panel A. Fraction 11 contained 42% 
of the total radioactivity, and nc+ +ther fraction con- 
tained more than 10% of the total. The recovery of 
radioactivity from each chromatographic run was at 
least 95%. The equivalent fractions from five separate 
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Fig. I, Purification! of [‘H]pyridoxylatcd tryptic peptida of HSA. A: 
anion-exchange HI?LC of total labeled tryptic peptides. Peptides wcrc 
resolved as de&ted in Section 2, and fractions { I .5 ml) were collected 
and analyzed for radioactivity. Fraction 11, from 5 separate runs, was 
pooled, lyophilizcd, dc-phosphorylated and resolved by anion-ex- 
change re-chromatography shown in (X.3). Dash&d line in (B) shows 
elution of IOOpgofalkaline phosphatasc. Radiolabclcd fractions 9-l I 
(0.5 ml) from m-chromatography were pooled and purified by rc- 
versed-phase HPLC in (C). Fractions 14 and I5 (05 ml) were collected 
for sequencing and amino acid analysis. 
runs were pooled, lyophilized, and treated wiht phos- 
phatase to remove the phosphate group. 
Rechromatography of the dephosphorylated sample 
separated the major labeled peptide from several un- 
labeled peptides (Fig. 1B). The PL-peptide had a shorter 
retention time on the anion-exchange columnt than the 
PLP-peptide. More than 95% of the total radioactivity 
was recoverd from reversed-phase HPLC within a sing!e 
broad band (Fig. 1C). The tow peak fractions were 
pooled for protein sequencing and amino acid analysis. 
Protein sequencing (Fig. 2) revealed ahomopnous pep- 
tide with the sequence Leu-Asp-Glu-Leu-Arg-Asp-Glu- 
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Fig. 2, Protein sequencing analysis of the primary pyridoxylated pep 
tide from HSA. The purified major labeled peptidc from Fig. IC was 
sequenced as described in Section 2, The number of picomoles o~cacl1 
residue which were recovered durinB 14 consecutive sequencing steps 
is indicated. The sequence given in the one letter code corresponds to 
Lcu-Asp-Glu-Leu-Arg-Asp-Glu-Gly-Xaa-Ala-Ser-Ser-Ala-Lys. Res- 
idue Xaa corresponds to the radiolabcled, pyridoxylated Lyslg”. No 
other residue was greater than IO% of the recovered amino acid. 
Gly-Xaa-Ala-Ser-Ser-Ala-Lys corresponding to resi- 
dues 182-195 in the known sequence of HSA [S]. 
Residue Xaa represents he modified L~s-*~~. An aliquot 
of the peptide was subjected to amino acid analysis, and 
the theoretical and experimental mino acid composi- 
tions were as follows: Ala (2 residues expected; experi- 
mental 1.9), Arg (1; 1.2), Asp (2; 1.7), Glu (2; 2.0), Gly 
(1; 1.2), Leu (2; 2.0), Lys (2; l.O), and Set (2; 2.0). The 
composition data are consistent with that obtained by 
peptide sequencing. 
4. DISCUSSION 
We utilized amino acid analysis and protein sequenc- 
ing of a purified peptide containing [3H]PLP to identify 
Lys’M as the primary PLP binding site in HSA. The 
isolation of this peptide, which contained more than 
40% of the total label, demonstrated resistance to 
trypsin cleavage at two sites within the peptide: Arglss 
and the PLP-modified Lys’“‘. Argla5 may be naturally 
resistant to trypsin digestion owing to its position in the 
HSA molecule or, alternatively, the phosphate ster of 
PLP may interact with Arg’*’ and inhibit cleavage. In- 
complete trypsin cleavage at ArglE5 and nearby sites 
would result in the production of other radiolabeled 
peptides containing Lys 190. This suggests that the 42% 
PLP labeling we found at Lyslw of HSA is a minimum 
estimate. Several different elution conditions and HPLC 
columns were used in attempts to resolve the early- 
eluting, radiolabeled peptides. However, it was not pos- 
sible to obtain, from these fractions, peptides of a 
quality suitable for sequencing. 
Our investigations failed to identify a PLP binding 
site in the vicinity of LYS~?~, which is the primary site of 
nonenzymatic glycoaylation (NEG) in HSA. The pK, 
accessibility, and microenvironment of specific Lys 
amino groups may determine the sites of Schiff base 
formation with a particular ligand. A phosphate bind- 
ing region on HSA has been proposed to play a role in 
site-specific NEG [12]. Furthermore, it was reported 
that a high concentration of PLP (10 mM) may block 
NEG sites of HSA and BSA [13,14]. However, our 
results indicate that PLP at physiological concentra- 
tions would not compete for the primary NEG site of 
HSA. Regardless, we cannot rule out the presence of a 
low affinity PLP or phosphate binding site in the region 
of Lysszs since only the major labeled peptide was 
purified and sequenced. 
Equilibrium binding data indicating that HSA has 
one high affinity and two or more nonspecific sites for 
PLP [3] are consistent with our identification of one 
primary site. Sequence differences in the PLP binding 
sites of HSA (Lys”“) and BSA (L~s”~‘““~) [S] support 
previous results which demonstrated differences in PLP 
binding to these albumins [3]. 
Identification of Lystgo as the specific PLP-binding 
residue on HSA allows for the use of PLP as a site- 
specific affinity probe of HSA and may permit the 
design of studies to elucidate the mechanisms which 
control PLP binding to HSA and regulate human PLP 
metabolism in normal and disease states. 
REFEKGNCES 
[1] Lumen& L., Brashcdr, R-E, and Li, T.-K. (1974) J. Lab. Clin. 
Med. 84, 334-343. 
[2] Fonda, M.L., Trauss, C. and Guempel, U.M. (1990) Ann. NY 
Acad, Sci. 58.5. 483-485. 
[3] Fonda, M.L., Trams, C. and Guempel, U.M. (1991) Arch. 
B&hem. Biophys, 288, 79-86. 
[4] McMcnamy, R,H, (1977) in: Albumin Structure, Function and 
Uses (Roscnocr, V. M., Orate, M. and Rothschild, M. A. eds.) 
Pergamon Press, New York, pp. 143-158. 
[S] Peters Jr., T. (193s) Adv. Prot. Chcm. 37, 161-245. 
[6] Dempsey, W.B. and Christensen, H.N. (1962) J. Biol. Chem. 237, 
1113-1120. 
[7] Harding, J.J. (1985) Adv. Prot. Chcm. 37, 247~2G9. 
[S] Feldhoff, R.C. and Leddcn, D.J. (1982) Fed. Proc. 41, GS3. 
[9] Stock, A., Ortanderl, F. and Pfleiderer, G. (196G) Biochcm. 2. 
344. 353-360. 
[IO] Raibdud, 0. and Goldberg, M.E. (1974) FEBS Lett. 40, 41-44. 
[I 1] Coburn, S.P. and Mahuren, J.D. (1956) Methods Bnzymol. 122, 
102-I 10. 
[II] Watkins, N.G., Net&t-Fisher, CL, Dyer, D.G., Thorpe, S.R. 
and Baynes, J.W. (1987) J. Biol. Chcm. 262, 7207-7212, 
[I31 Shcpard. DC., Hia. I.D. and Dain, J.A. (1985) Biochcm. Arch. 
I, 143-151. 
[14] Khatami, M., Zalman, S., David, I., Weiye, L. and Rockey, J.H. 
(1988) Life Sci. 43, 1725-1731. 
268 
